"Anti-Dyskinesia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of Parkinson disease (ANTIPARKINSON AGENTS) and those for the tardive dyskinesias.
| Descriptor ID |
D018726
|
| MeSH Number(s) |
D27.505.954.427.090
|
| Concept/Terms |
Anti-Dyskinesia Agents- Anti-Dyskinesia Agents
- Agents, Anti-Dyskinesia
- Anti Dyskinesia Agents
- Movement Disorder Agents
- Agents, Movement Disorder
- Disorder Agents, Movement
|
Below are MeSH descriptors whose meaning is more general than "Anti-Dyskinesia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Dyskinesia Agents".
This graph shows the total number of publications written about "Anti-Dyskinesia Agents" by people in this website by year, and whether "Anti-Dyskinesia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 3 | 2 | 5 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Dyskinesia Agents" by people in Profiles.
-
Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019 12; 90(12):1317-1323.
-
Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
-
Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014 Jan; 11(1):139-52.
-
Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov; 28(13):1775-83.
-
Jankovic J. Medical treatment of dystonia. Mov Disord. 2013 Jun 15; 28(7):1001-12.
-
Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013 Feb 04; 5(2):249-66.
-
Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
-
Ongkasuwan J, Courey M. The role of botulinum toxin in the management of airway compromise due to bilateral vocal fold paralysis. Curr Opin Otolaryngol Head Neck Surg. 2011 Dec; 19(6):444-8.
-
Barnes MA, Ho AS, Malhotra PS, Koltai PJ, Messner A. The use of botulinum toxin for pediatric cricopharyngeal achalasia. Int J Pediatr Otorhinolaryngol. 2011 Sep; 75(9):1210-4.
-
Messner A, Ho AS, Malhotra PS, Koltai PJ, Barnes MA. The use of botulinum toxin for pediatric cricopharyngeal achalasia. Int J Pediatr Otorhinolaryngol. 2011 Jun; 75(6):830-4.